Effectiveness of pneumococcal conjugate vaccine against hospital admissions for pneumonia in Australian children

a retrospective, population-based, record-linked cohort study

Parveen Fathima, Heather F. Gidding, Peter B. McIntyre, Thomas L. Snelling, Lisa McCallum, Nicholas de Klerk, Christopher C. Blyth, Bette Liu, Hannah C. Moore

    Research output: Contribution to journalArticleResearchpeer-review

    Abstract

    Background: Reductions in pneumonia hospitalisations following introduction of pneumococcal conjugate vaccines (PCVs) have been reported from high-incidence and low-incidence settings but long-term data comparing vaccinated with unvaccinated children are sparse.

    Methods: We did a retrospective, population-based, record-linkage cohort study in Australian children using administrative health data from the Western Australian Midwives' Notification System and New South Wales Perinatal Data Collection, and the birth and death registries in both states. PCV vaccination details, pneumonia-coded hospital admissions, and invasive pneumococcal disease notification records were individually linked for children born between 2001 and 2012. The primary outcome was defined as the first hospital admission for all-cause pneumonia. Cox models were used to calculate adjusted hazard ratios (HR) to estimate the effect of PCV doses on pneumonia-coded hospital admissions by Aboriginal status, birth period, remoteness, and pneumonia diagnostic category in children younger than 2 years. Person-time of follow-up time for each child started at birth and was censored at the earliest of first hospital admission for all-cause pneumonia, death, invalid PCV dose, when the child reached age 24 months, or the end date of the study period (Dec 31, 2013)

    Findings: The study cohort comprised 1 365 893 children liveborn between Jan 1, 2001, and Dec 31, 2012, of whom 66 484 (4·9%) were identified as Aboriginal. The overall rate for all-cause pneumonia hospital admissions for children younger than 2 years over the entire study period was 17·6/1000 child-years in Aboriginal children and 5·5/1000 child-years in non-Aboriginal children. Compared with children born between 2001 and 2004 (ie, the pre-universal PCV period), the incidence of pneumonia-coded hospital admissions decreased in both vaccinated (6·5 vs 5·7 per 1000 child-years [12% reduction, 95% CI 3–21; p=0·01]) and unvaccinated non-Aboriginal children (6·8 vs 3·7 [45% reduction; 41–49]) born 2005–12 (the universal PCV period); among Aboriginal children, declines were significant only among those vaccinated (27·4 vs 14·1 [49% reduction, 40–55]). Among Aboriginal children born 2005–12, the risk of pneumonia-coded hospital admission after three doses of PCV was lower than those unvaccinated (adjusted HR 0·83, 95% CI 0·65–0·99) but, among non-Aboriginal children, the risk was similar (adjusted HR 1·09, 0·98–1·22). Overall, remote-born Aboriginal children had the highest incidence of hospital admission for pneumonia and among children born 2005–12, the adjusted risk was 37% lower (adjusted HR 0·63, 95% CI 0·42–0·96) among those fully vaccinated than those unvaccinated.

    Interpretation: Reductions in pneumonia-coded hospital admissions in unvaccinated children predominated in non-Aboriginal children with low incidence of pneumonia but were not significant in Aboriginal children with high incidence. These findings have potential implications for measuring PCV effect using a non-specific endpoint such as all-cause pneumonia in high-incidence populations.

    Funding: Commonwealth Government Collaborative Research Infrastructure Strategy and Education Investment Fund Super Science Initiative and the Australian National Health and Medical Research Council.

    Original languageEnglish
    Pages (from-to)713-724
    Number of pages12
    JournalThe Lancet Child and Adolescent Health
    Volume3
    Issue number10
    DOIs
    Publication statusPublished - 1 Oct 2019

    Fingerprint

    Conjugate Vaccines
    Pneumococcal Vaccines
    Pneumonia
    Cohort Studies
    Population
    Incidence
    Parturition
    Disease Notification

    Cite this

    Fathima, Parveen ; Gidding, Heather F. ; McIntyre, Peter B. ; Snelling, Thomas L. ; McCallum, Lisa ; de Klerk, Nicholas ; Blyth, Christopher C. ; Liu, Bette ; Moore, Hannah C. / Effectiveness of pneumococcal conjugate vaccine against hospital admissions for pneumonia in Australian children : a retrospective, population-based, record-linked cohort study. In: The Lancet Child and Adolescent Health. 2019 ; Vol. 3, No. 10. pp. 713-724.
    @article{fc8d1c9cb6174107874f33bdbb2e008c,
    title = "Effectiveness of pneumococcal conjugate vaccine against hospital admissions for pneumonia in Australian children: a retrospective, population-based, record-linked cohort study",
    abstract = "Background: Reductions in pneumonia hospitalisations following introduction of pneumococcal conjugate vaccines (PCVs) have been reported from high-incidence and low-incidence settings but long-term data comparing vaccinated with unvaccinated children are sparse. Methods: We did a retrospective, population-based, record-linkage cohort study in Australian children using administrative health data from the Western Australian Midwives' Notification System and New South Wales Perinatal Data Collection, and the birth and death registries in both states. PCV vaccination details, pneumonia-coded hospital admissions, and invasive pneumococcal disease notification records were individually linked for children born between 2001 and 2012. The primary outcome was defined as the first hospital admission for all-cause pneumonia. Cox models were used to calculate adjusted hazard ratios (HR) to estimate the effect of PCV doses on pneumonia-coded hospital admissions by Aboriginal status, birth period, remoteness, and pneumonia diagnostic category in children younger than 2 years. Person-time of follow-up time for each child started at birth and was censored at the earliest of first hospital admission for all-cause pneumonia, death, invalid PCV dose, when the child reached age 24 months, or the end date of the study period (Dec 31, 2013) Findings: The study cohort comprised 1 365 893 children liveborn between Jan 1, 2001, and Dec 31, 2012, of whom 66 484 (4·9{\%}) were identified as Aboriginal. The overall rate for all-cause pneumonia hospital admissions for children younger than 2 years over the entire study period was 17·6/1000 child-years in Aboriginal children and 5·5/1000 child-years in non-Aboriginal children. Compared with children born between 2001 and 2004 (ie, the pre-universal PCV period), the incidence of pneumonia-coded hospital admissions decreased in both vaccinated (6·5 vs 5·7 per 1000 child-years [12{\%} reduction, 95{\%} CI 3–21; p=0·01]) and unvaccinated non-Aboriginal children (6·8 vs 3·7 [45{\%} reduction; 41–49]) born 2005–12 (the universal PCV period); among Aboriginal children, declines were significant only among those vaccinated (27·4 vs 14·1 [49{\%} reduction, 40–55]). Among Aboriginal children born 2005–12, the risk of pneumonia-coded hospital admission after three doses of PCV was lower than those unvaccinated (adjusted HR 0·83, 95{\%} CI 0·65–0·99) but, among non-Aboriginal children, the risk was similar (adjusted HR 1·09, 0·98–1·22). Overall, remote-born Aboriginal children had the highest incidence of hospital admission for pneumonia and among children born 2005–12, the adjusted risk was 37{\%} lower (adjusted HR 0·63, 95{\%} CI 0·42–0·96) among those fully vaccinated than those unvaccinated. Interpretation: Reductions in pneumonia-coded hospital admissions in unvaccinated children predominated in non-Aboriginal children with low incidence of pneumonia but were not significant in Aboriginal children with high incidence. These findings have potential implications for measuring PCV effect using a non-specific endpoint such as all-cause pneumonia in high-incidence populations. Funding: Commonwealth Government Collaborative Research Infrastructure Strategy and Education Investment Fund Super Science Initiative and the Australian National Health and Medical Research Council.",
    author = "Parveen Fathima and Gidding, {Heather F.} and McIntyre, {Peter B.} and Snelling, {Thomas L.} and Lisa McCallum and {de Klerk}, Nicholas and Blyth, {Christopher C.} and Bette Liu and Moore, {Hannah C.}",
    year = "2019",
    month = "10",
    day = "1",
    doi = "10.1016/S2352-4642(19)30249-4",
    language = "English",
    volume = "3",
    pages = "713--724",
    journal = "The Lancet Child and Adolescent Health",
    issn = "2352-4642",
    number = "10",

    }

    Effectiveness of pneumococcal conjugate vaccine against hospital admissions for pneumonia in Australian children : a retrospective, population-based, record-linked cohort study. / Fathima, Parveen; Gidding, Heather F.; McIntyre, Peter B.; Snelling, Thomas L.; McCallum, Lisa; de Klerk, Nicholas; Blyth, Christopher C.; Liu, Bette; Moore, Hannah C.

    In: The Lancet Child and Adolescent Health, Vol. 3, No. 10, 01.10.2019, p. 713-724.

    Research output: Contribution to journalArticleResearchpeer-review

    TY - JOUR

    T1 - Effectiveness of pneumococcal conjugate vaccine against hospital admissions for pneumonia in Australian children

    T2 - a retrospective, population-based, record-linked cohort study

    AU - Fathima, Parveen

    AU - Gidding, Heather F.

    AU - McIntyre, Peter B.

    AU - Snelling, Thomas L.

    AU - McCallum, Lisa

    AU - de Klerk, Nicholas

    AU - Blyth, Christopher C.

    AU - Liu, Bette

    AU - Moore, Hannah C.

    PY - 2019/10/1

    Y1 - 2019/10/1

    N2 - Background: Reductions in pneumonia hospitalisations following introduction of pneumococcal conjugate vaccines (PCVs) have been reported from high-incidence and low-incidence settings but long-term data comparing vaccinated with unvaccinated children are sparse. Methods: We did a retrospective, population-based, record-linkage cohort study in Australian children using administrative health data from the Western Australian Midwives' Notification System and New South Wales Perinatal Data Collection, and the birth and death registries in both states. PCV vaccination details, pneumonia-coded hospital admissions, and invasive pneumococcal disease notification records were individually linked for children born between 2001 and 2012. The primary outcome was defined as the first hospital admission for all-cause pneumonia. Cox models were used to calculate adjusted hazard ratios (HR) to estimate the effect of PCV doses on pneumonia-coded hospital admissions by Aboriginal status, birth period, remoteness, and pneumonia diagnostic category in children younger than 2 years. Person-time of follow-up time for each child started at birth and was censored at the earliest of first hospital admission for all-cause pneumonia, death, invalid PCV dose, when the child reached age 24 months, or the end date of the study period (Dec 31, 2013) Findings: The study cohort comprised 1 365 893 children liveborn between Jan 1, 2001, and Dec 31, 2012, of whom 66 484 (4·9%) were identified as Aboriginal. The overall rate for all-cause pneumonia hospital admissions for children younger than 2 years over the entire study period was 17·6/1000 child-years in Aboriginal children and 5·5/1000 child-years in non-Aboriginal children. Compared with children born between 2001 and 2004 (ie, the pre-universal PCV period), the incidence of pneumonia-coded hospital admissions decreased in both vaccinated (6·5 vs 5·7 per 1000 child-years [12% reduction, 95% CI 3–21; p=0·01]) and unvaccinated non-Aboriginal children (6·8 vs 3·7 [45% reduction; 41–49]) born 2005–12 (the universal PCV period); among Aboriginal children, declines were significant only among those vaccinated (27·4 vs 14·1 [49% reduction, 40–55]). Among Aboriginal children born 2005–12, the risk of pneumonia-coded hospital admission after three doses of PCV was lower than those unvaccinated (adjusted HR 0·83, 95% CI 0·65–0·99) but, among non-Aboriginal children, the risk was similar (adjusted HR 1·09, 0·98–1·22). Overall, remote-born Aboriginal children had the highest incidence of hospital admission for pneumonia and among children born 2005–12, the adjusted risk was 37% lower (adjusted HR 0·63, 95% CI 0·42–0·96) among those fully vaccinated than those unvaccinated. Interpretation: Reductions in pneumonia-coded hospital admissions in unvaccinated children predominated in non-Aboriginal children with low incidence of pneumonia but were not significant in Aboriginal children with high incidence. These findings have potential implications for measuring PCV effect using a non-specific endpoint such as all-cause pneumonia in high-incidence populations. Funding: Commonwealth Government Collaborative Research Infrastructure Strategy and Education Investment Fund Super Science Initiative and the Australian National Health and Medical Research Council.

    AB - Background: Reductions in pneumonia hospitalisations following introduction of pneumococcal conjugate vaccines (PCVs) have been reported from high-incidence and low-incidence settings but long-term data comparing vaccinated with unvaccinated children are sparse. Methods: We did a retrospective, population-based, record-linkage cohort study in Australian children using administrative health data from the Western Australian Midwives' Notification System and New South Wales Perinatal Data Collection, and the birth and death registries in both states. PCV vaccination details, pneumonia-coded hospital admissions, and invasive pneumococcal disease notification records were individually linked for children born between 2001 and 2012. The primary outcome was defined as the first hospital admission for all-cause pneumonia. Cox models were used to calculate adjusted hazard ratios (HR) to estimate the effect of PCV doses on pneumonia-coded hospital admissions by Aboriginal status, birth period, remoteness, and pneumonia diagnostic category in children younger than 2 years. Person-time of follow-up time for each child started at birth and was censored at the earliest of first hospital admission for all-cause pneumonia, death, invalid PCV dose, when the child reached age 24 months, or the end date of the study period (Dec 31, 2013) Findings: The study cohort comprised 1 365 893 children liveborn between Jan 1, 2001, and Dec 31, 2012, of whom 66 484 (4·9%) were identified as Aboriginal. The overall rate for all-cause pneumonia hospital admissions for children younger than 2 years over the entire study period was 17·6/1000 child-years in Aboriginal children and 5·5/1000 child-years in non-Aboriginal children. Compared with children born between 2001 and 2004 (ie, the pre-universal PCV period), the incidence of pneumonia-coded hospital admissions decreased in both vaccinated (6·5 vs 5·7 per 1000 child-years [12% reduction, 95% CI 3–21; p=0·01]) and unvaccinated non-Aboriginal children (6·8 vs 3·7 [45% reduction; 41–49]) born 2005–12 (the universal PCV period); among Aboriginal children, declines were significant only among those vaccinated (27·4 vs 14·1 [49% reduction, 40–55]). Among Aboriginal children born 2005–12, the risk of pneumonia-coded hospital admission after three doses of PCV was lower than those unvaccinated (adjusted HR 0·83, 95% CI 0·65–0·99) but, among non-Aboriginal children, the risk was similar (adjusted HR 1·09, 0·98–1·22). Overall, remote-born Aboriginal children had the highest incidence of hospital admission for pneumonia and among children born 2005–12, the adjusted risk was 37% lower (adjusted HR 0·63, 95% CI 0·42–0·96) among those fully vaccinated than those unvaccinated. Interpretation: Reductions in pneumonia-coded hospital admissions in unvaccinated children predominated in non-Aboriginal children with low incidence of pneumonia but were not significant in Aboriginal children with high incidence. These findings have potential implications for measuring PCV effect using a non-specific endpoint such as all-cause pneumonia in high-incidence populations. Funding: Commonwealth Government Collaborative Research Infrastructure Strategy and Education Investment Fund Super Science Initiative and the Australian National Health and Medical Research Council.

    UR - http://www.scopus.com/inward/record.url?scp=85071911147&partnerID=8YFLogxK

    U2 - 10.1016/S2352-4642(19)30249-4

    DO - 10.1016/S2352-4642(19)30249-4

    M3 - Article

    VL - 3

    SP - 713

    EP - 724

    JO - The Lancet Child and Adolescent Health

    JF - The Lancet Child and Adolescent Health

    SN - 2352-4642

    IS - 10

    ER -